Advertisement
Advertisement
ATOS
Atossa Therapeutics, Inc. Common Stock
4.98
USDSponsored
0.00
0.00%
Apr 10, 14:41 UTC -4
Open
ATOS Earnings Reports
Positive Surprise Ratio
ATOS beat 20 of 32 last estimates.
63%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$1.07
Implied change from Q4 25 (Revenue/ EPS)
--
/-65.26%
Implied change from Q1 25 (Revenue/ EPS)
--
/+42.67%
Atossa Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 25, 2026, ATOS reported earnings of -3.08 USD per share (EPS) for Q4 25, missing the estimate of -1.16 USD, resulting in a -165.45% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.78% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -1.07 USD, with revenue projected to reach -- USD, implying an decrease of -65.26% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Adagio Medical Holdings, Inc Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$0.31
Actual
-$0.16
Surprise
+49.40%
PAVmed Inc. Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$5.50
Actual
-$5.52
Surprise
-0.22%
American Shared Hospital Services
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.02
Actual
-$0.09
Surprise
-545.54%
NexGel, Inc Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.12
Surprise
-30.72%
ENDRA Life Sciences Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.25
Actual
-$3.26
Surprise
-159.84%
AngioDynamics, Inc.
Report Date
Apr 02, 2026 For Q3 26
Estimate
-$0.11
Actual
$0.02
Surprise
+117.83%
LENSAR, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.12
Surprise
-68.07%
Xtant Medical Holdings, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.00
Actual
$0.00
Surprise
+100.00%
FAQ
What were Atossa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Atossa Therapeutics, Inc. Common Stock reported EPS of -$3.08, missing estimates by -165.45%, and revenue of $0.00, 0% as expectations.
How did the market react to Atossa Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -1.78%, changed from $5.61 before the earnings release to $5.51 the day after.
When is Atossa Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Atossa Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$1.07 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement